TREATMENT OF MENOPAUSAL SYMPTOMS : A COMPARATIVE STUDY

Menopause is permanent cessation of menstruation resulting from the loss of ovarian follicular activity. Women suffer many troublesome problems after menopause resulting from estrogen deficiency. Aim of this study is to compare symptomatic response in Indian women using different medicine preparations for treatment of menopausal symptoms. It is an observational prospective study conducted in PMCH Gynae OPD from October 2017 to September 2019. Two hundred women were enrolled and assigned to different treatment groups. There was 90.32% decrease in hot flushes in E2V group while it was 87.09% in CEE group. Psychosomatic symptoms reduced by 75% and 70% in E2V and CEE group respectively. Sexual and urinary symptoms also got more improved when treated with estrogen preparations. Both estradiol valerate and conjugated estrogen were effective in reducing severity of hot flushes, psychosomatic symptoms, sexual and urinary symptoms as compared to isoflavones and placebo. Isoflavones had very little advantage over placebo

Download Full-text

Influence of Carteolol and Timolol on IOP and Visual Fields in Glaucoma: A Multi-Center, Double-Masked, Prospective Study

European Journal of Ophthalmology ◽

10.1177/112067219200200402 ◽

1992 ◽

Vol 2 (4) ◽

pp. 169-174 ◽

Cited By ~ 6

Author(s):

J. Flammer ◽

Y. Kitazawa ◽

L. Bonomi ◽

B. Mills ◽

M. Fsadni ◽

...

Keyword(s):

Visual Field ◽

Prospective Study ◽

Beta Blockers ◽

Visual Fields ◽

Visual Field Defects ◽

Eye Drops ◽

Treatment Groups ◽

Visual Field Damage ◽

One Year ◽

Field Defects

The influences of Carteolol and Timolol eye drops on intraocular pressure (IOP) and visual fields were compared in a multi-center, double-masked, prospective study. Two-hundred and forty eyes of 120 patients were initially included in the study, and 142 eyes of 72 patients fulfilled all the criteria for final statistical analysis. Both drugs significantly reduced IOP. The visual fields in both treatment groups did not change during one year of treatment. In both groups some patients improved slightly, and others deteriorated slightly. This indicates that locally applied beta-blockers may efficiently stop further progression of visual field defects in cases with increased IOP and early visual field damage. There was no difference between Carteolol and Timolol in this regard. The side effects were minimal, and there were no differences in their frequency or intensity in the two treatment groups.

Download Full-text

Impact of Menopausal Symptoms on Quality of Life in Indian Women

Indian Journal of Physiotherapy and Occupational Therapy - An International Journal ◽

10.37506/ijpot.v16i1.17780 ◽

2022 ◽

Vol 16 (1) ◽

Keyword(s):

Quality Of Life ◽

Menopausal Symptoms ◽

Indian Women

Download Full-text

The effect of soy-derived isoflavones over hot flushes, menopausal symptoms and mood in climacteric women with increased body mass index

Gynecological Endocrinology ◽

10.3109/09513590.2010.490614 ◽

2010 ◽

Vol 27 (5) ◽

pp. 307-313 ◽

Cited By ~ 15

Author(s):

Peter Chedraui ◽

Glenda San Miguel ◽

Gino Schwager

Keyword(s):

Body Mass Index ◽

Body Mass ◽

Menopausal Symptoms ◽

Hot Flushes

Download Full-text

Women’s views about physical activity as a treatment for vasomotor menopausal symptoms: a qualitative study

BMC Women s Health ◽

10.1186/s12905-020-01063-w ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Adèle Thomas ◽

Amanda J. Daley

Keyword(s):

Physical Activity ◽

Qualitative Study ◽

Healthcare Professionals ◽

Well Being ◽

Menopausal Symptoms ◽

Hot Flushes ◽

Physical Activity Interventions ◽

Night Sweats ◽

Randomised Controlled ◽

Women’S Views

Abstract Background Women commonly seek medical advice about menopausal symptoms. Although menopausal hormone therapy is the most effective treatment, many women prefer non-pharmacological treatments, such as physical activity. The effectiveness of physical activity has been inconclusive when assessed by randomised controlled trials, and it remains unclear how women feel about it as a possible treatment approach. The aim of the study was to explore symptomatic menopausal women’s views and experiences of physical activity as a treatment for vasomotor and other menopausal symptoms. Methods An in-depth qualitative study was embedded within a randomised controlled trial that assessed the effectiveness of physical activity as a treatment for vasomotor menopausal symptoms in previously inactive vasomotor symptomatic women. Participants were randomised to one of two physical activity interventions or a usual care group. Both physical activity interventions involved two one-to-one consultations, plus either supporting materials or access to physical activity support groups, over 6 months. Semi-structured interviews were conducted with 17 purposively selected participants from all three trial groups after they had completed trial follow-up. Interviews were audio recorded, transcribed verbatim, and analysed by constant comparison. Results All participants talked positively about physical activity as a treatment for their menopausal symptoms, with most reporting participation had improved their hot flushes and night sweats. They reported that they had experienced improved sleep, physical health and psychological well-being. Those who received the physical activity plus social-support intervention reported their ability to cope with their menopausal symptoms had improved. Many participants commented that they would prefer doctors to discuss physical activity as a possible treatment for their hot flushes and night sweats, before offering medication. Conclusions Based on the views and experiences of the women who participated in this study, healthcare professionals should continue discussing physical activity as a potential first treatment option with menopausal women. Furthermore, healthcare professionals should ensure they prepare, support, and encourage these women both physically and emotionally. Trial registration ISRCTN ISRCTN06495625 Registered 10/11/2010

Download Full-text

High-Dose Cyclophosphamide and Dexamethasone in Paraquat Poisoning: A Prospective Study

Human & Experimental Toxicology ◽

10.1177/096032719201100212 ◽

1992 ◽

Vol 11 (2) ◽

pp. 129-134 ◽

Cited By ~ 40

Author(s):

J.H. Perriëns ◽

S. Benimadho ◽

I. Lie Kiauw ◽

J. Wisse ◽

H. Chee

Keyword(s):

Prospective Study ◽

Standard Treatment ◽

Case Fatality ◽

Fluid Replacement ◽

High Dose ◽

Serum Concentrations ◽

Treatment Groups ◽

Paraquat Poisoning ◽

A Prospective Study ◽

Urine Testing

Between March 1986 and March 1988, 47 consecutive patients, whose paraquat intoxication was confirmed by urine testing, were enrolled in a prospective study on the treatment of paraquat poisoning. Fourteen received a standard treatment regimen consisting of fluid replacement and oral absorbents, and 33 received high-dose cyclophosphamide and dexamethasone, in addition to standard therapy. The case fatality rate in both treatment groups (63 and 61%) was similar. In addition, all 26 patients whose paraquat serum concentrations were measured and who had a probability of survival of less than 65% according the survival curve of Hart et al. died, regardless of therapy. These included four in the cyclophosphamide/dexamethasone group and two in the standard treatment group who had prior survival probabilities between 50 and 65%. This indicated that the cut-off curve relating mortality and paraquat serum concentrations was similar in both treatment groups. High-dose cyclophosphamide/dexamethasone treatment is unlikely to improve the prognosis of paraquat poisoning.

Download Full-text

Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women

Menopause International: The Integrated Journal of Postreproductive Health ◽

10.1258/175404507781605596 ◽

2007 ◽

Vol 13 (3) ◽

pp. 124-131 ◽

Cited By ~ 6

Author(s):

L A Mattsson ◽

S Skouby ◽

M Rees ◽

J Heikkinen ◽

M Kudela ◽

...

Keyword(s):

Hormone Replacement Therapy ◽

Replacement Therapy ◽

Postmenopausal Women ◽

Dose Regimen ◽

Hormone Replacement ◽

Secondary Outcome ◽

Estradiol Valerate ◽

Hot Flushes ◽

Double Blind ◽

Early Postmenopausal Women

Objective. Continuous combined hormone replacement therapy (ccHRT) based on estradiol valerate (E2V) and medroxyprogesterone acetate (MPA) is effective for relief of menopausal symptoms three years or more after the menopause. This study was undertaken to examine the efficacy and tolerability of ccHRT in early postmenopausal women (last menstrual period 1.3 years before study entry). Study design. This was a 52-week, randomized, double-blind, multinational study of ccHRT comprising three different dose combinations of E2V/MPA in 459 early postmenopausal non-hysterectomized women experiencing 30 or more moderate to severe hot flushes a week and/or vasomotor symptoms requiring treatment. Main outcomes measures. The primary endpoint was change in frequency and severity of moderate to severe hot flushes at 12 weeks. Secondary outcome measures included number of bleeding days and evaluation of tolerability. Results. The frequency of hot flushes was reduced by ≥70% after one month ( P<0.001 for all doses at week 2 onwards), with little evidence of statistically different dose effects. Severity of flushing was also attenuated by ccHRT. Mean number of bleeding days fell to <1 per 28-day cycle at 52 weeks. Rates of amenorrhoea approached 80–90% at the end of the study, but were significantly lower at several time points with the highest-dose regimen (2 mg E2V + 5 mg MPA) than with the lower-dose options (1 mg E2V + 2.5 mg MPA and 1 mg E2V + 5 mg MPA; P<0.05). Adverse events declined in frequency over time with all regimens but throughout the study were more numerous with the highest-dose regimen than with lower doses ( P= 0.0002). Conclusions. Continuous combined HRT was effective for the relief of climacteric symptoms in early postmenopausal women and was well tolerated.

Download Full-text

Menopausal symptoms, such as hot flushes and reduced quality of life, can be influenced by the pollen extract Femal - a double-blind, placebo-controlled, randomised parallel study

Focus on Alternative and Complementary Therapies ◽

10.1111/j.2042-7166.2005.tb00539.x ◽

2010 ◽

Vol 10 ◽

pp. 57-57

Author(s):

K Winther ◽

E Rein

Keyword(s):

Quality Of Life ◽

Menopausal Symptoms ◽

Pollen Extract ◽

Hot Flushes ◽

Parallel Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy of a standardised acupuncture approach for women with bothersome menopausal symptoms: a pragmatic randomised study in primary care (the ACOM study)

BMJ Open ◽

10.1136/bmjopen-2018-023637 ◽

2019 ◽

Vol 9 (1) ◽

pp. e023637 ◽

Cited By ~ 4

Author(s):

Kamma Sundgaard Lund ◽

Volkert Siersma ◽

John Brodersen ◽

Frans Boch Waldorff

Keyword(s):

Primary Care ◽

Adverse Effects ◽

Intervention Group ◽

Physical Symptoms ◽

Menopausal Symptoms ◽

Control Group ◽

Acupuncture Points ◽

Hot Flushes ◽

Emotional Symptoms ◽

Sleeping Problems

ObjectiveTo investigate the efficacy of a standardised brief acupuncture approach for women with moderate-to-severe menopausal symptoms.DesignRandomised and controlled, with 1:1 allocation to the intervention group or the control group. The assessor and the statistician were blinded.SettingNine Danish primary care practices.Participants70 women with moderate-to-severe menopausal symptoms and nine general practitioners with accredited education in acupuncture.InterventionThe acupuncture style was western medical with a standardised approach in the predefined acupuncture points CV-3, CV-4, LR-8, SP-6 and SP-9. The intervention group received one treatment for five consecutive weeks. The control group was offered treatment after 6 weeks.Main outcome measuresOutcomes were the differences between the randomisation groups in changes to mean scores using the scales in the MenoScores Questionnaire, measured from baseline to week 6. The primary outcome was the hot flushes scale; the secondary outcomes were the other scales in the questionnaire. All analyses were based on intention-to-treat analysis.Results36 participants received the intervention, and 34 participants were in the control group. Four participants dropped out before week 6. The acupuncture intervention significantly decreased hot flushes: Δ −1.6 (95% CI [−2.3 to −0.8]; p<0.0001), day-and-night sweats: Δ −1.2 (95% CI [−2.0 to −0.4]; p=0.0056), general sweating: Δ −0.9(95% CI [−1.6 to −0.2]; p=0.0086), menopausal-specific sleeping problems: Δ −1.8 (95% CI [−2.7 to −1.0]; p<0.0001), emotional symptoms: Δ −3.4 (95% CI [−5.3 to −1.4]; p=0.0008), physical symptoms: Δ −1.7 (95% CI [−3 to −0.4]; p=0.010) and skin and hair symptoms: Δ −1.5 (95% CI [−2.5 to −0.6]; p=0.0021) compared with the control group at the 6-week follow-up. The pattern of decrease in hot flushes, emotional symptoms, skin and hair symptoms was already apparent 3 weeks into the study. Mild potential adverse effects were reported by four participants, but no severe adverse effects were reported.ConclusionsThe standardised and brief acupuncture treatment produced a fast and clinically relevant reduction in moderate-to-severe menopausal symptoms during the six-week intervention. No severe adverse effects were reported.Trial registration numberNCT02746497; Results.

Download Full-text